Daiichi Sankyo stock (JP3475350009): FY2025 oncology surge and ambitious 5-year plan

Daiichi Sankyo reported FY2025 financial results with 12.6% revenue growth driven by oncology, forecasting 7.4% revenue increase for FY2026 amid ADC expansion plans.

Daiichi Sankyo released its FY2025 financial results and 5-Year Business Plan on May 12, 2026, highlighting a 12.6% revenue growth fueled by its oncology portfolio, particularly antibody-drug conjugates (ADCs). The company aims to become a global top five oncology player by 2035 with over three trillion yen in FY2030 revenue, up from 2.1 trillion yen in FY2025, according to Daiichi Sankyo FY2025 Presentation as of 05/12/2026.

For FY2026, Daiichi Sankyo forecasts revenue of JPY 2,280 billion, a 7.4% increase, with core operating profit at JPY 360 billion, as detailed in Investing.com as of 05/12/2026. The oncology segment, led by Enhertu and other DXd ADCs, is central to this strategy, targeting over 20 new indications by 2030.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Daiichi Sankyo Co Ltd
• Sector/industry: Pharmaceuticals / Oncology
• Headquarters/country: Japan
• Core markets: Japan, US, Europe
• Key revenue drivers: Oncology ADCs like Enhertu
• Home exchange/listing venue: Tokyo Stock Exchange (4568)
• Trading currency: JPY

Daiichi Sankyo: core business model

Daiichi Sankyo Co Ltd develops and commercializes innovative medicines, with a strong focus on oncology through its DXd ADC platform. The company, headquartered in Tokyo, Japan, operates globally with key partnerships like AstraZeneca for Enhertu, approved for HER2-positive breast cancer and other indications in the US and Europe, per Daiichi Sankyo US as of 05/12/2026.

Beyond oncology, Daiichi Sankyo maintains a diversified portfolio in cardiovascular and rare diseases, but oncology now drives growth, contributing significantly to FY2025 results published on May 12, 2026.

Main revenue and product drivers for Daiichi Sankyo

Oncology products, especially Enhertu, propelled FY2025 revenue growth of 12.6%, with the company planning rapid expansion of its ADC portfolio to reach over 700,000 patients annually by 2035, according to its 5-Year Business Plan released May 12, 2026, via Japan Times as of 05/12/2026.

Enhertu generated substantial sales amid global demand, though Daiichi Sankyo is diversifying to mitigate patent expiry risks by advancing five key ADCs across multiple indications by 2030.

Industry trends and competitive position

The ADC market is expanding rapidly, with Daiichi Sankyo positioning itself as a leader through its DXd technology. Competitors include Seagen (Pfizer) and ImmunoGen (AbbVie), but Daiichi Sankyo's pipeline targets broad cancer types, enhancing its competitive edge in the US market where oncology spending exceeds $200 billion annually.

Why Daiichi Sankyo matters for US investors

Daiichi Sankyo's US operations via daiichisankyo.us and partnerships expose it to the world's largest pharma market. Enhertu sales in the US, approved by the FDA for multiple indications, link the stock to American healthcare spending trends, making it relevant for US retail investors tracking global biotech.

Conclusion

Daiichi Sankyo's FY2025 results underscore oncology momentum, with FY2026 guidance signaling continued growth via ADCs. The 5-Year Plan outlines aggressive targets amid supply chain challenges noted in recent reports. Investors monitor execution in competitive markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.